Corebridge Financial (NYSE:CRBG) Stock

Corebridge Financial

Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments namely Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.

Earnings

Large Cap

Mid Cap

News

Contracts

Markets

Trading Ideas

Brighthouse Financial, Inc. - Common Stock

CRBG

Corebridge Financial, Inc. (NYSE: CRBG) recently launched its new retirement product, Corebridge MarketLock Annuity, through its American General Life Insurance subsidiary.

Corebridge Enhances Retirement Solutions With MarketLock Annuity

Growth,Chart.,Glowing,Rise,Up,Arrow,On,The,Top,Of

Equities

Movers

DELL

MNDY

MSTR

ONON

PODD

SMCI

Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets &amp; more positive news.

MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio?

Intraday Update

ADTH

ASTS

AWIN

BMTX

BRSH

BSFC

COIN

CRKN

DADA

EXTR

EYEN

FFIE

FLNT

GAMB

GOOS

GWAV

KULR

LSDI

LSPD

MGNI

NICE

OMER

PEGY

REKR

RELI

SBOW

SDOT

SINT

SPIR

TIRX

TRUP

TSRI

WOOF

Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Corebridge Financial Inc

Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 84.21 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $351.900 million which beat the analyst consensus estimate of $343.357 million by 2.49 percent. This is a 32.91 percent increase over sales of $264.758 million the same period last year.

Earnings Beats

RELY

Remitly Global Q4 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $351.900M Beat $343.357M Estimate

Bausch Health Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.52 billion by 1.38 percent. This is a 6.27 percent increase over sales of $2.41 billion the same period last year.

Bausch Health Companies Q4 Sales $2.56B Beat $2.52B Estimate

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.35 by 2.86 percent. This is a 12.5 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $182.35 million which beat the analyst consensus estimate of $177.96 million by 2.46 percent. This is a 11.60 percent increase over sales of $163.40 million the same period last year.

SBRA

Sabra Health Care REIT Q4 2024 FFO $0.36 Beats $0.35 Estimate, Sales $182.35M Beat $177.96M Estimate

Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.06 by 16.67 percent. This is a 22.22 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $270.164 million which beat the analyst consensus estimate of $257.247 million by 5.02 percent. This is a 34.00 percent increase over sales of $201.618 million the same period last year.

KVYO

Klaviyo Q4 2024 Adj. EPS $0.07 Beats $0.06 Estimate, Sales $270.164M Beat $257.247M Estimate

Management

Herbalife Appoints Stephan Gratziani As Chief Executive Officer, Effective May 1

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.53 by 73.58 percent. This is a 87.76 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $747.31 million which beat the analyst consensus estimate of $713.44 million by 4.75 percent. This is a 15.65 percent increase over sales of $646.21 million the same period last year.

BMRN

Biomarin Pharmaceutical Q4 Adj $0.92 Beats $0.53 Estimate, Sales $747.31M Beat $713.44M Estimate

Christina succeeds Brad West, who announced his retirement in 2024 after eight years as COO. West will remain with the company as Chief of Staff through June 2025 to ensure a seamless transition.

NDLS

Noodles & Company Names Joe Christina As President And COO

Earnings Misses

TFII

TFI International Q4 2024 Adj. EPS $1.19 Misses $1.60 Estimate, Sales $2.077B Miss $2.171B Estimate

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) sees FY2025 sales of $115.000 million-$125.000 million vs $121.32 million analyst estimate.

Guidance

Outset Medical Sees FY2025 Sales $115.000M-$125.000M vs $121.32M Est

MGRC

McGrath Sees FY25 Revenue $920M-$970M Up From $911M YoY; Adj EBITDA $345M-$360M.

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 37.29 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $29.47 million which beat the analyst consensus estimate of $28.47 million by 3.49 percent. This is a 3.41 percent decrease over sales of $30.51 million the same period last year.

Outset Medical Q4 Adj $(0.37) Beats $(0.41) Estimate, Sales $29.47M Beat $28.47M Estimate

Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) reported quarterly earnings of $0.95 per share which met the analyst consensus estimate. This is a 10.47 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $624.20 million which beat the analyst consensus estimate of $620.22 million by 0.64 percent. This is a 11.23 percent increase over sales of $561.20 million the same period last year.

CHDN

Churchill Downs Q4 2024 GAAP EPS $0.95, Inline, Sales $624.20M Beat $620.22M Estimate

Penumbra Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) is trading higher after the company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/02/n43796948/penumbra-inc-reports-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">fourth-quarter earnings</a>.
The medical device company reported:
<ul>
<li>Adjusted EPS of 97 cents, up from 76 cents a year ago, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 90 cents</a>.</li>
<li>Sales of $315.52 million, up 10.8% year over year and beating the consensus of $311.55 million.</li>
<li>Global thrombectomy product Q4 sales grew to $220.1 million, an increase of 15.4% in reported and constant currency</li>
<li>U.S. thrombectomy product sales increased by 27.3%.</li>
<li>Global embolization and access product revenues grew to $95.4 million in the fourth quarter of 2024, an increase of 1.6%, or 1.5% in constant currency</li>
<li>U.S. embolization and access product revenue increased by 8.9%.</li>
<li>Operating income reached $42.8 million, with an adjusted&nbsp;operating income of $48.6 million&nbsp;in the fourth quarter of 2024.</li>
<li>Q4 net income reached $33.7 million, and adjusted EBITDA was $63.7 million, with margins of 10.7% and 19.8%, respectively.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42534137/penumbra-is-poised-to-gain-share-in-an-expanding-market-says-bullish-analyst" rel="noreferrer noopener">Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst</a>
<h2 class="wp-block-heading">Penumbra Guidance</h2>
The company forecasts fiscal year 2025 sales of $1.34 billion-$1.36 billion versus a consensus of $1.36 billion.
Penumbra projects the U.S. thrombectomy franchise will grow 19% to 20% year over year, driven primarily by its computer-assisted vacuum thrombectomy products.
The company also expects gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to 13% to 14% of revenue for 2025.
Analyst reactions:
<ul>
<li>Baird maintains the Outperform rating on Penumbra, raising the price target <a href="https://www.benzinga.com/quote/PEN/analyst-ratings" target="_blank" rel="noreferrer noopener">from $305 to $328</a>.</li>
<li>Needham reiterates Penumbra&#8217;s Hold rating.</li>
<li>Morgan Stanley maintains Penumbra with an Equal-Weight, raising the price target from $240 to $260.</li>
<li>Piper Sandler reiterates Penumbra with an Overweight, increasing the price target from $250 to $330.</li>
<li>Wells Fargo also reaffirms Penumbra&#8217;s Overweight rating, with a price target of $305, up from $275.</li>
<li>UBS analyst maintains Penumbra with a Buy and raises the price target from $305 to $320.</li>
<li>Canaccord Genuity maintains the Buy rating on Penumbra and raises the price target from $323 to $340.</li>
<li>Truist Securities reaffirms the Buy rating for Penumbra and raises the price target from $285 to $325.</li>
<li>RBC Capital maintains Penumbra with an Outperform rating and raises the price target from $285 to $313.</li>
<li>JP Morgan maintains Penumbra with an Overweight rating and raises the price target from $230 to $285.</li>
</ul>
Price Action: Penumbra stock is up 11.3% at $301.89 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43815436/supernus-pharmaceuticals-stock-falls-on-disappointing-data-from-treatment-resistant-depression-trial" target="_blank" rel="noreferrer noopener">Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial</a></li>
</ul>
Image: Shutterstock

Health Care

Price Target

Analyst Ratings

General

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

WIIM

VMAR

Vision Marine Technologies shares are trading higher after the company announced an enhanced collaboration with Electrified Marina.

Vision Marine Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) ("Vision Marine" or the "Company"), a company specializing in electric marine propulsion, is pleased to announce an enhanced collaboration with Electrified Marina, the nation's only 100% electric watercraft dealer.
&nbsp;
Co-founded by Erick Pinzon, Jr., a former Tesla service and charging infrastructure specialist, Electrified Marina has become a key player in the electric boating sector. Known for its deep industry knowledge, Electrified Marina has built a strong reputation by selling and operating both high-powered electric boats and low-powered electric cruisers, making electric boating accessible to a diverse range of customers.
Through this strengthened partnership, Vision Marine will provide Electrified Marina with additional resources to bolster its role as a leading distributor and ambassador for Vision Marine's E-Motion&#x2122; electric propulsion technology. This initiative aims to expand consumer access to high-performance, zero-emission boating solutions along the East Coast.

Vision Marine Technologies Strengthens Partnership With Electrified Marina To Propel Electric Boating On The East Coast

McGrath RentCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRC#NASDAQ">MGRC</a>) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.49 by 6.04 percent. The company reported quarterly sales of $243.700 million which missed the analyst consensus estimate of $246.926 million by 1.31 percent. This is a 9.98 percent increase over sales of $221.588 million the same period last year.

McGrath RentCorp Q4 2024 Adj. EPS $1.58 Beats $1.49 Estimate, Sales $243.700M Miss $246.926M Estimate

DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) with a Neutral and lowers the price target from $17 to $16.5.

DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $16.5

<h4>Key Takeaways:</h4>
<ul>
<li>Eternal Beauty has filed for a Hong Kong IPO, reporting its profit rose 20% year-on-year in the first half of its current financial year</li>
<li>The perfume seller plans to use funds from the listing to further expand its self-owned brands</li>
</ul>
A new beauty pageant is shaping up on the Hong Kong Stock Exchange, following last year&rsquo;s hot listing of popular cosmetics brand&nbsp;Mao Geping&nbsp;(1318.HK). That share sale brought in suitors left and right and was ultimately oversubscribed by more than 900 times. As investors clamored for a piece of the company, its stock soared on its opening day, closing up 76%.
The stock hasn&rsquo;t disappointed since then, either, continuing to climb to its current level that&rsquo;s up nearly 150% from the IPO price. The stock&rsquo;s hot reception may be inspiring perfume major&nbsp;Eternal Beauty Holdings Ltd.&nbsp;to restart its earlier attempt at a Hong Kong listing.
Its new&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107126/documents/sehk25020701004.pdf">listing document</a>&nbsp;filed earlier this month shows Eternal Beauty&rsquo;s revenue has been rising steadily from 1.68 billion yuan ($231 million) in its fiscal year through March 2022 to 1.86 billion yuan in its fiscal year through March 2024. Its profit over that period rose from 171 million yuan to 207 million yuan. Its revenue for the six months through last September &ndash; the first half of its current fiscal year &ndash; rose 14.2% year-on-year to 1.06 billion yuan, while its profit over that time rose 20% to 116 million yuan.
The company&rsquo;s mainstay is perfume, though it also deals in other products like color cosmetics, skincare and personal care products, eyewear and home fragrances. Its revenue comes primarily from the sale of its own-branded products, and from managing brands for other companies. It currently provides such management services to 66 outside brands, including such big names as Herm&egrave;s, Van Cleef &amp; Arpels, Chopard, Albion and Laura Mercier.
The company logged one of its earliest milestones in 1987 when it was authorized to distribute a French company&rsquo;s perfumes in China. It recorded another in 1999 when it started developing its own Santa Monica eyewear brand. It currently offers three product categories under the brand, including five Santa Monica perfumes launched in 2022, positioned as entry-level premium products.
<h4>Demand for beauty</h4>
Eternal Beauty is no doubt encouraged by Mao Geping&rsquo;s success story, reflecting the resilience of cosmetic sales in China despite the current weak consumer market. Even though people may need to economize a little during the slowdown, many may still feel compelled to spend on making themselves look better.
Data from China&rsquo;s National Statistics Bureau shows that cosmetics sales in China rose from 394 billion yuan in 2022 to 436 billion yuan last year. Eternal Beauty&rsquo;s listing document also reveals that the scale of China&rsquo;s retail perfume market jumped from 14.6 billion yuan in 2018 to 26.1 billion yuan in 2023, growing around 12.3% annually. The growth is expected to continue at a similar rate, reaching 47.7 billion yuan in 2028.
Against the backdrop of such strong growth, Eternal Beauty stands out for its substantial first-mover advantage. The company was founded by Hong Kong businessman Lau Kui Wing in 1980 and set up a branch on the Chinese Mainland in 1987 introducing international perfume brands to the market. As China&rsquo;s economy boomed over the next three decades, Eternal Beauty also thrived on growing demand for its products from the country&rsquo;s emerging middle class.
According to third-party market data in its listing document, Eternal Beauty was China&rsquo;s third largest perfume seller in terms of retail sales in 2023, and was also the only brand management company for other top perfume makers. Its leading position in a rising industry has given it an advantage as a market old-timer over later arrivals to China&rsquo;s beauty scene.
Its long history has also given the company a store network that would make its rivals green with envy. That network includes 7,500 retailers in over 400 Chinese cities as of last September, in addition to over 100 of its own self-operated brick-and-mortar retail stores. It also hawks its wares online on e-commerce and social media platforms.
<h4>Expanding self-owned brands</h4>
As in many businesses, self-brand operation for perfume makers like Eternal Beauty typically delivers better profits compared with distributing and managing other brands. The company already has such experience through its development of the Santa Monica brand, and it plans to use money from the IPO to further expand its own brand stable as well as acquire and invest in other brands. That, in turn, should help to not only boost its revenue, but also improve its gross margin.
In valuation terms, Mao Geping has set a high standard by logging a trailing price-to-earnings (P/E) ratio of 40 times. Much of that may owe to the fact that the company owns its own brands, which helped it generate a profit of close to 500 million yuan in the first half of last year. While Eternal Beauty has plenty of experience in perfume sales and brand management, its weaker profit profile may make Mao Geping an inappropriate comparison.
Instead, a better comparison might be Hong Kong&rsquo;s&nbsp;Sa Sa International&nbsp;(0178.HK), which trades at a more down-to-earth trailing P/E ratio of 13.7 times. Using Sa Sa&rsquo;s P/E multiple and an annual profit forecast of HK$230 million would give Eternal Beauty a market value of about HK$3.2 billion ($411 million) &ndash; not huge, but also not small change for the latest beauty queen to list in Hong Kong.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

IPOs

Eternal Beauty Struts Its Stuff As Hong Kong's Newest IPO Contestant

Jones Trading analyst Jason Weaver maintains Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) with a Buy and maintains $15 price target.

SEVN

Jones Trading Maintains Buy on Seven Hills Realty Trust, Maintains $15 Price Target

CAKE

CAVA

FWRG

JACK

KRUS

PTLO

PZZA

RRGB

SHAK

STKS

TXRH

WING

YOSH

Shares of restaurant companies are trading lower. The sector may be down after Wingstop reported a Q4 revenue miss and reported an increase in the cost of food, beverage and packaging costs, including a rise in the cost bone-in chicken wings.

Press Releases

Corebridge Financial Announces Third Quarter 2024 Results

Corebridge Financial Announces Launch of Secondary Offering of Common Stock by AIG

Corebridge Financial Announces Pricing of Secondary Offering of Common Stock by AIG

Corebridge Financial Announces Updates to Board of Directors

Corebridge Financial Research Finds Retirement Expectations of Women Don't Always Meet Realities

Polly Klane to Join Corebridge Financial as General Counsel

Corebridge Financial Announces Keith Gubbay and Colin J. Parris Appointed to Board of Directors

Corebridge Financial Schedules Announcement of Fourth Quarter and Full Year 2024 Financial Results

Corebridge Financial Launches New Digital Experience for Retirement Plan Participants

Comments

Corebridge Financial

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga